Taxpayers May Have Overpaid by More Than $1 Billion for Mylan's EpiPen: Senator - NBC Boston
National & International News
The day’s top national and international news

Taxpayers May Have Overpaid by More Than $1 Billion for Mylan's EpiPen: Senator

Find NBC Boston in your area

Channel 10 on most providers

Channel 60 and 8 Over the Air

    processing...

    NEWSLETTERS

    Mylan CEO Heather Bresch faces Congress to answer questions on EpiPen price hikes. (Published Wednesday, Sept. 21, 2016)

    American taxpayers may have overpaid by as much as $1.27 billion for EpiPen anti-allergy devices over the course of a decade, a U.S. senator said Wednesday. 

    That is nearly three times the $465 million that EpiPen’s owner, drugmaker Mylan, last October said it agreed to pay the federal government to settle claims it overcharged the government-run Medicaid system for the devices. 

    As CNBC reports, Sen. Chuck Grassley, R-Iowa, said it looks like Mylan overcharged taxpayers for years by knowingly classifying the brand-name EpiPen as a generic drug, resulting in the company paying a lower rebate rate to Medicaid.

    A spokeswoman for Mylan had no immediate comment.